Leiden University

Site:	Leiden University
Address:
City:	Leiden
State:
Zip:	2333
Country:	Netherlands

11 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [asc]	NCT#
3	Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate	Terminated	Closed	Imatinib	NCT00956072
3	Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST	Active, not recruiting	Closed	Imatinib	NCT02413736
	GIST: Assessment of Tumor Mutations and TKI Plasma Exposure	Recruiting	Not yet activated	Imatinib + Sunitinib + Regorafenib	NCT02331914
1	Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia	Terminated	Closed	LOP628	NCT02221505
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
2	A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors	Terminated	Closed	Olaratumab (IMC-3G3)	NCT01316263
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105